These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 18779839)

  • 1. Controlling HIV infection: HIV co-receptor gets the finger.
    Kelleher AD; Purcell DF
    Immunol Cell Biol; 2008; 86(8):641-2. PubMed ID: 18779839
    [No Abstract]   [Full Text] [Related]  

  • 2. Positive results with autologous transplant of ZFN-modified CD4 T-cells: a step toward a practical, functional cure for HIV.
    AIDS Patient Care STDS; 2011 Nov; 25(11):693. PubMed ID: 22023317
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeted gene editing enters clinic.
    Ledford H
    Nature; 2011 Mar; 471(7336):16. PubMed ID: 21368795
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5.
    Maier DA; Brennan AL; Jiang S; Binder-Scholl GK; Lee G; Plesa G; Zheng Z; Cotte J; Carpenito C; Wood T; Spratt SK; Ando D; Gregory P; Holmes MC; Perez EE; Riley JL; Carroll RG; June CH; Levine BL
    Hum Gene Ther; 2013 Mar; 24(3):245-58. PubMed ID: 23360514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual zinc-finger nucleases block HIV infection.
    Durand CM; Siliciano RF
    Blood; 2014 Jan; 123(1):2-3. PubMed ID: 24385492
    [No Abstract]   [Full Text] [Related]  

  • 6. Autologous CCR5-modified CD4 T-cells effective in HAART nonresponders.
    AIDS Patient Care STDS; 2011 Nov; 25(11):693. PubMed ID: 22132424
    [No Abstract]   [Full Text] [Related]  

  • 7. CC-chemokine receptor 5 genotypes and in vitro susceptibility to HIV-1 of a cohort of British HIV-exposed uninfected homosexual men.
    Aarons E; Fernandez M; Rees A; McClure M; Weber J
    AIDS; 1997 Apr; 11(5):688-9. PubMed ID: 9108955
    [No Abstract]   [Full Text] [Related]  

  • 8. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo.
    Holt N; Wang J; Kim K; Friedman G; Wang X; Taupin V; Crooks GM; Kohn DB; Gregory PD; Holmes MC; Cannon PM
    Nat Biotechnol; 2010 Aug; 28(8):839-47. PubMed ID: 20601939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery.
    Swan CH; Bühler B; Steinberger P; Tschan MP; Barbas CF; Torbett BE
    Gene Ther; 2006 Oct; 13(20):1480-92. PubMed ID: 16738691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of protection from HIV infection by the mutant HIV coreceptor CCR5 in intravenously HIV infected hemophilia patients.
    Malo A; Rommel F; Bogner J; Gruber R; Schramm W; Goebel FD; Riethmüller G; Wank R
    Immunobiology; 1998 Feb; 198(4):485-8. PubMed ID: 9562872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The isolation of novel phage display-derived human recombinant antibodies against CCR5, the major co-receptor of HIV.
    Shimoni M; Herschhorn A; Britan-Rosich Y; Kotler M; Benhar I; Hizi A
    Viral Immunol; 2013 Aug; 26(4):277-90. PubMed ID: 23941674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-clinical modeling of CCR5 knockout in human hematopoietic stem cells by zinc finger nucleases using humanized mice.
    Hofer U; Henley JE; Exline CM; Mulhern O; Lopez E; Cannon PM
    J Infect Dis; 2013 Nov; 208 Suppl 2(Suppl 2):S160-4. PubMed ID: 24151324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression.
    Butticaz C; Ciuffi A; Muñoz M; Thomas J; Bridge A; Pebernard S; Iggo R; Meylan P; Telenti A
    Antivir Ther; 2003 Oct; 8(5):373-7. PubMed ID: 14640383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of CCR5 on activated CD4 T cells in HIV-infected Indians.
    Dubey S; Khalid M; Wesley C; Khan SA; Wanchu A; Jameel S
    J Clin Virol; 2008 Sep; 43(1):25-31. PubMed ID: 18462992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dichotomous effects of Plasmodium falciparum antigens on expression of human immunodeficiency virus (HIV) coreceptors and on infectability of CD4 cells by HIV.
    Moriuchi M; Moriuchi H; Mon HM; Kanbara H
    J Infect Dis; 2002 Oct; 186(8):1194-7. PubMed ID: 12355376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases.
    Perez EE; Wang J; Miller JC; Jouvenot Y; Kim KA; Liu O; Wang N; Lee G; Bartsevich VV; Lee YL; Guschin DY; Rupniewski I; Waite AJ; Carpenito C; Carroll RG; Orange JS; Urnov FD; Rebar EJ; Ando D; Gregory PD; Riley JL; Holmes MC; June CH
    Nat Biotechnol; 2008 Jul; 26(7):808-16. PubMed ID: 18587387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of cell-delivered gene therapy for the treatment of HIV/AIDS.
    Symonds GP; Johnstone HA; Millington ML; Boyd MP; Burke BP; Breton LR
    Immunol Res; 2010 Dec; 48(1-3):84-98. PubMed ID: 20737298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 CCR5 gene therapy will fail unless it is combined with a suicide gene.
    Pandit A; de Boer RJ
    Sci Rep; 2015 Dec; 5():18088. PubMed ID: 26674113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel CCR5 mutation selectively affects immunoreactivity and fusogenic property of the HIV co-receptor.
    Zhao XY; Lee SS; Wong KH; Chan KC; He ZM; Ma S; Ng F; Chan CC; Ho T; Ng MH; Zheng BJ
    AIDS; 2004 Aug; 18(12):1729-32. PubMed ID: 15280786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene editing using a zinc-finger nuclease mimicking the CCR5Δ32 mutation induces resistance to CCR5-using HIV-1.
    Badia R; Riveira-Muñoz E; Clotet B; Esté JA; Ballana E
    J Antimicrob Chemother; 2014 Jul; 69(7):1755-9. PubMed ID: 24651827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.